Prognostic Impact of Cell of Origin in Limited-Stage Diffuse Large B-Cell Lymphoma Treated With R-CHOP With or Without Radiation Therapy
Paul Youn(University of Rochester Medical Center), Louis S. Constine(University of Rochester Medical Center), Jonathan W. Friedberg(University of Rochester), S. Dhakal(Bir Hospital), Paul M. Barr(University of Rochester Medical Center), Carla Casulo(University of Rochester Medical Center), Michael Cummings(University of Rochester Medical Center), Richard Burack(University of Rochester Medical Center)
International Journal of Radiation Oncology*Biology*Physics
October 1, 2016
Cited by 1
Related Papers
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2017|1.3k
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
|Nature Medicine|2015|1.1k